# Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia

> **NCT02928094** · PHASE3 · UNKNOWN · sponsor: **Angionetics Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Angina, Stable

## Interventions

- **BIOLOGICAL:** Ad5FGF-4
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02928094
- **Lead sponsor:** Angionetics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2022-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02928094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02928094, "Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02928094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*